About ACTIV
The goal of ACTIV is to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and therapeutics.
Overview
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership led by the National Institutes of Health (NIH) and coordinated by the Foundation for the National Institutes of Health (FNIH) to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.
ACTIV brings together NIH with its sibling agencies in the Department of Health and Human Services, including the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA); other government agencies, including the Department of Defense (DOD) and Department of Veterans Affairs (VA); the European Medicines Agency (EMA); and representatives from academia, philanthropic organizations and biopharmaceutical companies.
The COVID-19 pandemic is an unprecedented global crisis that has been met with a swift and extraordinary response. The research community is sifting through more than 100 potential preventives and treatments. However, lack of coordination could make interpretation and comparison of the results impossible because resources, like patients for trials or testing facilities, are not unlimited.
With limited resources, there is a need to coordinate and streamline processes to make the best use of biomedical research resources and testing of preclinical compounds. Also, there is a need to prioritize the most promising vaccine candidates and move them into clinical trials in a way that is safe and efficient.
For more information, visit the NIH website.
Submit Ideas to ACTIV
Read the FAQs for submitting clinical and preclinical candidate compounds to the NIH’s portal. Submit therapeutic candidates to ACTIV
FNIH Contact
Katherine Thompson, Director of Communications, kthompson@fnih.org
The FNIH takes research integrity very seriously. For any questions or concerns, please contact ResearchIntegrity@FNIH.org.
Goals:
The goals of ACTIV are to:
- Develop a collaborative, streamlined forum to identify preclinical treatments
- Accelerate clinical testing of the most promising vaccines and treatments
- Improve clinical trial capacity and effectiveness
- Accelerate the evaluation of vaccine candidates to enable rapid authorization or approval
Scientific Publications
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 (The ATTACC, ACTIV-4a, and REMAP-CAP Investigators) – The New England Journal of Medicine
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 (The REMAP-CAP, ACTIV-4a, and ATTACC Investigators) – The New England Journal of Medicine
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics – Annals of Internal Medicine
Monoclonal Antibody for Patients with Covid-19. Reply – The New England Journal of Medicine
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 – The New England Journal of Medicine
COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations – International Journal of Laboratory Hematology
Prospects for a safe COVID-19 vaccine – Science Translational Medicine
Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics – CellPress
ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics – CellPress
Accelerating Development of SARS-Cov-2 Vaccines: The Role for Controlled Human Infection Models – The New England Journal of Medicine
Media
NLM NCBI Insights (December 1, 2022): Announcing the NCBI SARS-CoV-2 Variant Calling Pipeline and Related Data Products
Duke Health (October 19, 2022): Study Finds No Benefit to Taking Fluvoxamine for COVID-19 Symptoms
Duke Clinical Research Institute (August 10, 2021): Clinical Study Expands Platform to Test Medications to Treat Mild-to-Moderate COVID-19
Policy Forum (May 29, 2021): A strategic approach to COVID-19 vaccine R&D
NIH Statement (June 21, 2021): ACTIV4a moderate state COVID-19 study arm stopped
Brigham and Women’s Hospital Press Release (June 21, 2021)): NIH ACTIV-4B COVID-19 outpatient thrombosis prevention trial ends early
NCATS Statement (June 16, 2021): Enrollment open: The NIH ACTIV-6 Clinical Trial will study Ivermectin as an at-home treatment for mild to moderate COVID-19.
NIH Press Release (April 22, 2021): Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients begins
NIH Press Release (April 19, 2021): Large clinical trial to study repurposed drugs to treat COVID-19 symptoms
NIH Press Release (March 8, 2021): Statement on NIH starting to enrollment for third trial of blood clotting treatments for COVID -19
NIH Press Release (March 4, 2021): NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies
NIH Press Release (February 12, 2021): Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial
NIH Press Release (February 8, 2021): Clinical trial in hospitalized COVID-19 patients evaluates long-acting antibody therapy
NIH Press Release (January 5, 2021): Large clinical trial will test combination monoclonal antibody therapy for mild/moderate COVID-19
NIH Press Release (October 16, 2020): NIH begins large clinical trial to test immune modulators for treatment of COVID-19
NIH Press Release (September 23, 2020): Fourth large-scale COVID-19 vaccine trial begins in the United States
NIH Press Release (September 10, 2020): NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19
NIH Press Release (August 4, 2020): NIH clinical trial to test antibodies and other experimental therapeutics for mild and moderate COVID-19
NIH Press Release (July 27, 2020): Phase 3 clinical trial of investigational vaccine for COVID-19 begins
NIH Press Release (April 17, 2020): NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options